Tolvaptan in the very elderly with acute decompensated heart failure- a therapeutic option worth of consideration

Kaynakça (12)

1. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12 220 index admissions in Leicestershire 1993-2001. Heart 2003; 89: 615-20
2. Mizuno M, Kajimoto K, Sato N, Yumino D, Minami Y, Murai K, et al. Clinical profile, management, and mortality in very-elderly patients hospitalized with acute decompensated heart failure: An analysis from the ATTEND registry. Eur J Intern Med 2016; 27: 80-5
3. Felker GM, Adams KF Jr, Konstam MA, O'Connor CM, Gheorghiade M. The problem of decompensated heart failure: nomenclature, classification, and risk stratification. Am Heart J 2003; 145 (2 Suppl): S18-25
4. Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol 2012; 59: 2145-53
5. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71
6. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332- 43
7. Felker GM, Mentz RJ, Adams KF, Cole RT, Egnaczyk GF, Patel CB, et al. Tolvaptan in patients hospitalized with acute heart failure: Rationale and design of the TACTICS and the SECRET of CHF trials. Circ Heart Fail 2015; 8: 997-1005
8. Goldsmith SR. A new approach to treatment of acute heart failure. J Cardiol 2016; 67: 395-8
9. Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 2016; 67: 399-405
10. Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, et al. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study). Int Heart J 2015; 56: 137-43
11. Niikura H, Iijima R, Anzai H, Kogame N, Fukui R, Takenaka H, et al. The clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure. Anatol J Cardiol 2017; 18: 206-12
12. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients h